To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study
Clinical trial NCT05656079 · UNKNOWN
Trial details
- NCT number
- NCT05656079
- Sponsor
- Shanghai Pudong Hospital
- Status
- UNKNOWN
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-01
- Primary completion
- 2024-09-01
- Enrollment
- 204
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.